Cell and gene therapy logistics moves living cells, not a stable chemical compound, between a clinical site and a manufacturing facility and back again as a patient-specific or donor-derived product. A patient's own T-cells, collected by apheresis, or a batch of donor-derived cells get frozen, shipped to a manufacturing site for genetic modification or expansion, frozen again, shipped back, and thawed at bedside for infusion. Every one of those cells has to survive two or more freeze and thaw cycles and a shipping route that can span a continent, which is a harder logistics problem than moving a stable vial of protein.
This is why cell and gene therapy sits apart from ordinary biologics logistics even though both are patient-critical. The cargo is alive at the cellular level until it is frozen, and its value cannot be restored by remaking a lost batch on short notice the way a commercial drug can.
Autologous and allogeneic paths diverge
An autologous therapy is made from the patient's own cells: one collection produces one dose for one named patient, and there is no inventory to fall back on if that shipment fails. An allogeneic therapy is made from a healthy donor's cells, manufactured in batches, and can be frozen and held as inventory the way a conventional biologic is. That difference changes the logistics model completely. Autologous shipping is a single, scheduled, one-to-one chain run against a named patient's calendar. Allogeneic shipping looks more like distributing a frozen commercial product: batch it, store it, ship it to demand, and replace it from stock if one shipment is lost.
Cryogenic shipping and vapor-phase nitrogen
Cell viability drops sharply if freezing is uncontrolled or if cryopreserved cells warm even briefly, so most cell and gene therapy product ships in vapor-phase liquid nitrogen dry shippers holding the payload below -150°C for days to weeks, with no liquid nitrogen in direct contact with the product. See cryogenic shipping for how that is held in transit. This is far colder than dry ice, which bottoms out around -78°C, warm enough that a cryopreserved cell product would still slowly lose viability if it relied on dry ice alone for a multi-day shipment. Some starting material, the patient's apheresis collection before it is frozen, instead moves briefly at conventional 2-8°C refrigerated temperatures on its first short leg to the manufacturing site, before cryopreservation begins.
Chain of identity and chain of custody
Chain of identity confirms that the cells returned to the clinic are the same cells that left the patient. For an autologous therapy, the starting material and the final product are one continuous physical thing, so a mislabeled or swapped unit is not a paperwork error, it is a therapy assigned to the wrong person's genetic material. Chain of custody is a separate, parallel requirement: an unbroken, timestamped record of every handoff, every temperature reading, and every person who touched the shipment from collection to infusion. Regulators and manufacturing quality teams audit both records independently, because a shipment can carry a perfect temperature log and still fail chain of identity if a barcode scan was skipped at one handoff.
Vein-to-vein time drives the schedule
Vein-to-vein time is the total elapsed time from collecting the patient's cells to reinfusing the finished product, and it is the metric that governs the entire logistics design. The patients waiting on many cell and gene therapies are relapsed or heavily pretreated and can deteriorate while they wait, so a manufacturing slot, an outbound shipping leg, an inbound return leg, and a hospital infusion suite booking all have to be scheduled against each other as one continuous appointment, not four independent bookings. A delay at any single step pushes the same patient's treatment date, not just a shipment's delivery date.
Failure means a re-collection, not a re-ship
Losing an ordinary cold chain shipment means resending stock from a warehouse. Losing an autologous cell therapy shipment usually means asking the patient to undergo apheresis again, which may not be clinically possible if their disease has progressed, and rebooking a manufacturing slot that can be weeks out. That asymmetry is why autologous logistics runs on dedicated couriers, redundant temperature monitoring, and manual chain-of-custody checks at every handoff, instead of the batch buffers and standard carrier networks that protect conventional freight.
Allogeneic product is the honest exception: because it is manufactured and frozen ahead of demand, a failed shipment can often be replaced from existing inventory much like any other frozen biologic, and does not need the same one-shipment-only handling. Apheresis centers, cell therapy manufacturers, transplant and oncology treatment centers, and carriers qualified under frameworks such as IATA CEIV Pharma all sit inside this chain, alongside the quality teams who sign off on every temperature record before a dose is allowed to reach the infusion suite.